-
#EAU19 Great talk by@piet_ost on value of PSMA-PET in men with hormone-sensitive#BCR. Yes we scan! Contrary, limited value yet in#nmCRPC. Thank you for highlighting our data pic.twitter.com/P63REdR9xZ
Prikaži ovu nit -
#eau19 Prof Albers recommends#PSMA PET in all men with#nmCRPC The value of this is not proven. All large CRPC studies to date are based on conventional imaging. PSMA-PET is useful in hormone-sensitive BCR, but men wit high-risk! M0CRPC primarily need treatment, not PET imaging pic.twitter.com/XUdVfqBaLn
Prikaži ovu nit -
Great news for patients suffering from
#nmCRPC in the US. This approval marks another important milestone in our fight against#cancer. Great to see Bayer Oncology growing. Proud of this terrific accomplishment of our#Orion and#Bayer team. Well done, team!https://twitter.com/BayerPharma/status/1156360517625307136 … -
maybe, but only within in clinical trials and certainly not in men with
#nmCRPC and short PSA-DT. -
All about
#nmCRPC. Tagged on http://bit.ly/Lk3CSf -
Fruitful discussion ABOUT
#nmCRPC. The role of#apalutamide and how to integrate#PSMA In daily clinical practice. Now on my way back to Spain, tomorrow some work and on Sunday@maratonvalenciapic.twitter.com/kpyFkjgPjM
-
Day 4 of
#ESMO18 has been a busy one so far! Keep a lookout right here for#ClinicalUpdates from Barbara Burtness of@YaleMed on#HeadandNeckCancer,@DrChoueiri on#RenalCellCarcinoma, and Simon Crabb of@unisouthampton on#nmCRPC!@myESMO#CaxTx#CTSMpic.twitter.com/RcJpngTSoD
-
#NEWS: Bayer receives approval from@US_FDA on new#nmCRPC treatment http://bit.ly/News_Bayer -
This is really interesting, looking forward to the data releases! Here is an article I researched looking at
#WhatHCPsThink about nmCRPC... straight to the source insights.#prostatecancer#nmCRPC#hcsm#pcsmhttps://creation.co/knowledge/healthcare-professionals-excited-by-emerging-treatments-for-prostate-cancer/ … -
A massive thanks to
@ProfJOSullivan for joining us at#ESMO18 to give his perspective on treating patients with#nmCRPC, full interview here soon!#CaxTx#Genitourinary#GUCancer#PCSM#ProstateCancer@myESMO#PatientCarepic.twitter.com/aqEc3GeVv1
-
@UsTOOHQ FYI: CME/CNE certified#nmCRPC webinar with a great panel. Hope you can make it! https://www.carevive.com/improving-management-nmcrpc/ … -
Over 174,000 new cases of prostate cancer will be diagnosed in the U.S. in 2019. This weekend, Bayer is at
@ThePCRI's 2019#ProstateCancer Patient Conference to discuss a treatment option for#nmCRPC. pic.twitter.com/DDPm1KJXWh
-
Join us and
#GoPlaid this Nov to raise awareness for#ProstateCancer! Visit http://www.ProStateUniversity.com to learn more.#MedEd#Cancer#nmCRPC pic.twitter.com/AfuB9f5zQn
-
@Bayer gets closer to have#darolutamide as a potential treatment option for men with#nmCRPC http://www.pharmaceuticaldaily.com/bayer-gets-closer-to-have-darolutamide-as-a-potential-treatment-option-for-men-with-nmcrpc/ …pic.twitter.com/tuTvbeReFG
-
The MW CEPAC will now vote on the comparative clinical effectiveness and overall economic value for antiandrogen therapies for
#nmCRPC#ProstateCancer. http://www.beaconliveweb.com/join?jrd=aWNlcjJ8OTc5Nzk3fElDRVJ8QXR0ZW5kZWV8IHwgfA … -
Going to
#EAU20? Join us in#Amsterdam on Saturday, 21 March for our "Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer" symposium.#nmCRPC Learn more and register at https://peervoice.com/nmCRPC-Amsterdam …pic.twitter.com/ol2Hvael92
-
#NEWS: New treatment for men with#nmCRPC from#Bayer receives positive#CHMP opinion http://bit.ly/News_Bayer -
Darolutamide: Approved For
#nmCRPC.#EverydayUrology article by Neal Shore, MD, FACS@AtlanticUrology on the evolving treatment landscape, preclinical and clinical data on darolutamide, and ongoing considerations for treating pts with nmCRPC on UroToday > http://bit.ly/2KcNVFz pic.twitter.com/1tGm1ptsQy
-
VIDEO: Research highlights in
#nmCRPC:#PROSPER and#SPARTAN studies, w/@AarmstrongDuke@DukeGUCancer: http://ow.ly/oPXy30lNcJB@ASCO@ASTRO_org@SUO_YUO#GU18#ProstateCancer#PCSM#prostatecancerawarenessmonth#GUPath#ClinicalTrials#CTSM#HCSM#GUSM#Osteomimicry -
Shorter
#PSA Doubling Time Associated with Increased Risk for Death in#nmCRPC https://www.docwirenews.com/conference-coverage/shorter-psa-doubling-time-associated-with-increased-risk-for-death-in-nmcrpc/ … via@mydocwire
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.